Alnylam Pharmaceuticals (ALNY) EBT Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) EBT Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -0.10% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1,140.26% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 71.54% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.15% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 88.57% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 9,460.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,460.35% |
| Dec 31, 2025 | 144.47% |
| Sep 30, 2025 | 358.20% |
| Jun 30, 2025 | -216.63% |
| Mar 31, 2025 | 96.28% |
| Dec 31, 2024 | -40.87% |
| Sep 30, 2024 | -172.09% |
| Jun 30, 2024 | 95.93% |
| Mar 31, 2024 | 63.11% |
| Dec 31, 2023 | 33.49% |
| Sep 30, 2023 | 137.13% |
| Jun 30, 2023 | 0.17% |
| Mar 31, 2023 | 27.99% |
| Dec 31, 2022 | 20.47% |
| Sep 30, 2022 | -98.76% |
| Jun 30, 2022 | -45.85% |
| Mar 31, 2022 | -20.11% |
| Dec 31, 2021 | -6.86% |
| Sep 30, 2021 | 19.10% |
| Jun 30, 2021 | -5.86% |